论文部分内容阅读
目的观察FOLFOX4方案一线治疗30例老年晚期食管鳞癌的疗效和不良反应。方法应用奥沙利铂(L-OHP)85mg/m2静脉滴注,第1天;亚叶酸钙(CF)200mg/m2静脉滴注,第1、2天;5-氟脲嘧啶(5-FU)400mg/m2静脉推注,第1、2天,5-FU600mg/m2持续静脉滴注22h第1、2天,14天为1周期。结果客观缓解率为46·7%;中位疾病进展时间为5·8个月;1年生存率为44·6%。骨髓抑制发生率为68·3%,恶心呕吐发生率为47·6%,外周神经毒性发生率为49·2%。结论 FOLFOX4方案一线治疗老年晚期食管鳞癌疗效较好,毒副反应较轻,值得进一步研究。
Objective To observe the efficacy and side effects of FOLFOX4 regimen in the treatment of 30 elderly patients with advanced esophageal squamous cell carcinoma. Methods The intravenous drip of oxaliplatin (L-OHP) at 85mg / m2 on day 1; 200mg / m2 of leucovorin (CF) on day 1,2; ) 400mg / m2 intravenous injection, 1,2 days, 5-FU600mg / m2 continuous intravenous infusion of 22h 1,2 days, 14 days for a cycle. Results The objective response rate was 46.7%. The median progression time was 5.8 months. The 1-year survival rate was 44.6%. The incidence of myelosuppression was 68.3%, nausea and vomiting was 47.6%, and peripheral neurotoxicity was 49.2%. Conclusion FOLFOX4 first-line treatment of elderly patients with advanced esophageal squamous cell carcinoma of the better efficacy, less toxic side effects, it is worth further study.